

AWARD NUMBER: W81XWH-17-1-0587

TITLE: Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease

PRINCIPAL INVESTIGATOR: Ali Keshavarzian, MD

CONTRACTING ORGANIZATION: Rush University Medical Center

REPORT DATE: September 2020

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE SEPTEMBER 2020	2. REPORT TYPE Annual Progress Report	3. DATES COVERED 1SEPT2019 - 31AUG2020
---	---	--

4. TITLE AND SUBTITLE Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease	5a. CONTRACT NUMBER W81XWH-17-1-0587
	5b. GRANT NUMBER PD160030 P2
	5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S) Ali Keshavarzian, MD E-Mail: ali_keshavarzian@rush.edu	5d. PROJECT NUMBER
	5e. TASK NUMBER
	5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Rush University Medical Center Jennifer Garcia 1653 Congress Parkway Chicago, IL 60612-3833	8. PERFORMING ORGANIZATION REPORT NUMBER
---	---

9. SPONSORING AGENCY NAME AND ADDRESS. U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012	10. SPONSOR/MONITOR'S ACRONYM(S)
	11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
The current project will analyze the gut microbiome and metabolites from PD patients and controls, and employ clinically relevant mouse models to determine how metabolites produced by the microbiome from dietary substrates affect motor symptoms. We propose to test whether directly regulating microbial metabolite profiles using "designer" dietary fibers and probiotics offers new avenues for ameliorating PD-like symptoms. During this reporting period 17 new human subjects were successfully recruited at this performance site.

15. SUBJECT TERMS
Parkinson's disease, human subjects, intestinal microbiome, stool specimens, gut-brain axis

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 10	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Accomplishments.....	4
4. Impact.....	5
5. Changes/Problems.....	6
6. Products, Inventions, Patent Applications, and/or Licenses.....	6-7
7. Participants & Other Collaborating Organizations.....	7
8. Special Reporting Requirements.....	7-8
9. Appendices.....	N/A

ANNUAL REPORT W81XWH-17-0587 PD160030 P2 YEAR 3
Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease

INTRODUCTION: The current project will analyze the gut microbiome and metabolites from PD patients and controls, and employ clinically relevant mouse models to determine how metabolites produced by the microbiome from dietary substrates affect motor symptoms. We propose to test whether directly regulating microbial metabolite profiles using “designer” dietary fibers and probiotics offers new avenues for ameliorating PD-like symptoms. During this reporting period 12 new human subjects (75% of targeted enrollment) were successfully recruited at the RUMC site to result in a total of 45 human subjects recruited (75% of targeted enrollment) in the first 3 years which partially meets our proposed goal. We have also made remarkable progress on the animal studies, defining specific diets that impact motor deficits in a mouse model of PD, and initiating mechanism of action studies. We have advanced the objectives of the project either on time, or in some cases ahead of schedule. The project has, to date, not experienced any major setbacks.

1. **KEYWORDS:** Parkinson's disease, human subjects, intestinal microbiome, stool specimens, gut-brain axis, intestinal bacteria, dietary fiber, short chain fatty acids

- **ACCOMPLISHMENTS:** During this Y3 reporting period 12 new human subjects were successfully recruited at this Rush University Medical Center performance site. This achieved 75% of the targeted goal of 12/16 subjects for this performance site for the Y3 period as well as the partial targeted total of 45/49 human subjects proposed for the first 3 years.

- **What were the major goals of the project?**

- **Major goals of the project as stated in the approved SOW:**

Major Task 1: Recruitment and Microbiome Sequencing

Subtask 1- subject recruitment and sample collection. 12 month target of 12/16 human subjects with stool and tissue collection successfully recruited. 75% completed

Subtask 2- microbiome sequencing / metagenomics. 24 month timeline. 80% completed

Subtask 3- SCFA analysis for stool and serum. 12 month timeline. 70% completed

Major Task 2: Animal colonization and phenotyping

Subtask 1 – colonization of mice with human microbiota 36 month timeline. 75% completed

Subtask 2 – microbiome profiling. 36 month timeline. 75% completed

Subtask 2 – motor testing, neuroinflammation status. 36 month timeline. 75% completed

Subtask 3 – AAV cloning and injection. 6 month timeline. 50% completed

Subtask 4 – CLARITY analysis and electrophysiology. 36 month timeline. 60% completed

Major Task 3: Fiber testing and treatment of animals

Subtask 1 – treat PD mice with fibers and motor tests. 12 month timeline. 100% completed

Subtask 2 – treat PD mice with “optimized” fibers & test 36 month timeline. 100% completed

What was accomplished under these goals?

Activities accomplished in this quarter include: 1) partially reached our 36 month goal for recruitment, with the target of 49 subjects; 45 subjects were already recruited ; 2) colonization of germ-free WT and ASO mice with human microbiota; 3) SCFA treatment of SPF mice followed by motor testing; 4) feeding of SCFAs to SPF mice and analysis of neuroinflammation; 5) production and treatment of animals with prebiotic fibers, and 6)

motor testing mice fed prebiotic fibers. We are excited to report that acetate feeding to SPF animals showed an effect on motor symptoms. Namely, feeding designer prebiotic diets enriched in 20% butyrate or acetate each improved motor symptoms in mice, whereas the 20% propionate diet did not have this effect, showing specificity for different SCFAs in our mouse model of PD. Further, we show that butyrate reduces activation of microglia in vitro, and thus may affect neuroinflammation in vivo. Finally, we have profiled the transcriptome of microglia from brain regions of mice fed SCFAs, and find preliminarily very interesting results that we will fully describe in the next Quarterly Progress Report. There have been no setbacks or failures to achieve a goal, and the project is progressing on the proposed timeline or in some cases such as the microglia studies, ahead of schedule.

Figure legend: Beta-Acids inhibit SCFA production, therefore we fed beta-acids to ASO mice (an animal model of PD), and observe that treatment reduces the weight reduction phenotype (panel A), improves performance in motor tests (panel B), and lowers pro-inflammatory cytokine TNF- α in the midbrain and serum (panel C). These new results strongly support the central hypothesis of the project, that SCFAs modulate brain inflammation to impact motor symptoms in a PD mouse model.

What opportunities for training and professional development has the project provided?

- "Nothing to Report." For the Rush University Medical Center site.

How were the results disseminated to communities of interest?

- "Nothing to Report." For the Rush University Medical Center site.

What do you plan to do during the next reporting period to accomplish the goals? Activities for next reporting period. 1) In the Year 4 of the Project, Dr. Keshavarzian's team at RUMC will continue vigorous patient and subject recruitment and sample collection (target for Year 4 for RUMC is 11 subjects). So far we have succeeded in hitting 92% of our 3 year enrollment target goal for human subjects recruitment (45/49). 2) Microbiome sequencing and SCFA analysis will be done in batches. 3) Dr. Mazmanian's group will analyze motor symptoms, neuroinflammation and pathophysiology in the "humanized" mouse models following prebiotic treatment. 4) We will evaluate short chain fatty acid (SCFA) levels in the prebiotic treated mice. 5) Dr. Gradinaru's group will image brain tissues from these mice. 6) Drs. Mazmanian and Hamaker will finish the "optimized" prebiotic diets.

2. IMPACT:

- **What was the impact on the development of the principal discipline(s) of the project?** *Rush University Medical Center site and Dr. Keshavarzian's team achieved the targeted new human subject recruitment and enrollment goal (12/16; total 45/49 for 3 years) which is required for the success of the project. The animal studies at Caltech further corroborated the preliminary data for a role by SCFAs in motor symptoms in mice.*
- **What was the impact on other disciplines?** "Nothing to Report." For the Rush University Medical Center site.
- **What was the impact on technology transfer?** "Nothing to Report." For the Rush University Medical Center site.

- **What was the impact on society beyond science and technology?** "Nothing to Report." For the Rush University Medical Center site.

3. CHANGES/PROBLEMS:

- **Changes in approach and reasons for change** "Nothing to Report." For the Rush University Medical Center site.
- **Actual or anticipated problems or delays and actions or plans to resolve them** "Nothing to Report." For the Rush University Medical Center site.
- **Changes that had a significant impact on expenditures** "Nothing to Report." For the Rush University Medical Center site.
- **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents** "Nothing to Report." For the Rush University Medical Center site.
- **Significant changes in use or care of human subjects** "Nothing to Report." For the Rush University Medical Center site.
- **Significant changes in use or care of vertebrate animals.** "Nothing to Report." For the Rush University Medical Center site.
- **Significant changes in use of biohazards and/or select agents.** "Nothing to Report." For the Rush University Medical Center site.

4. PRODUCTS:

- **Publications, conference papers, and presentations.** "Nothing to Report." For the Rush University Medical Center site.
- **Journal publications.** "Nothing to Report." For the Rush University Medical Center site.
- **Books or other non-periodical, one-time publications.** "Nothing to Report." For the Rush University Medical Center site.
- **Other publications, conference papers, and presentations.** "Nothing to Report." For the Rush University Medical Center site.

- **Website(s) or other Internet site(s).** "Nothing to Report." For the Rush University Medical Center site.
- **Technologies or techniques.** "Nothing to Report." For the Rush University Medical Center site.
- **Inventions, patent applications, and/or licenses.** "Nothing to Report." For the Rush University Medical Center site.
- **Other Products.** "Nothing to Report." For the Rush University Medical Center site.

5. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

- **What individuals have worked on the project?**
- **For the Rush University Medical Center site:**

Name: Ali Keshavarzian, MD

Project Role: RUMC Site PI

Researcher Identifier (e.g. ORCID ID): ORCID 0000-0002-7969-3369.

Nearest person month worked: 1.2 pm.

Contribution to Project: Dr. Keshavarzian has directed the project at RUMC and regularly consults with Dr. Mazmanian and his team by conference call and Skype. He meets with the Rush team weekly.

Name: Leonard Verhagen, MD

Project Role: RUMC Neurologist/PD Specialist, Co-Investigator

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 0.3 pm

Contribution to Project: Dr. Pal has left RUMC employment, Dr. Verhagen a renowned Movement Disorder and PD specialist assists in recruiting PD subjects and performs the medical evaluation of them as well as healthy subjects and obtains informed consent. He meets with Dr. Keshavarzian weekly.

Name: Gabriella Sanzo, BS

Project Role: Clinical Coordinator

Researcher Identifier (e.g. ORCID ID):

Nearest person month worked: 4.8 pm

Contribution to Project: Ms. Sanzo assists in recruiting subjects and performs the initial instructions and chart evaluation of them including administering questionnaires and assists with informed consent and pays the subjects. She meets with Dr. Pal each day and with Dr. Keshavarzian weekly or more often.

- **Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?** "Nothing to Report." For the Rush University Medical Center site.
- **What other organizations were involved as partners?** "Nothing to Report." For the Rush University Medical Center site.

6. SPECIAL REPORTING REQUIREMENTS

- **COLLABORATIVE AWARDS:** N/A

- **QUAD CHART:** Quad Chart for Rush University Medical Center site.

Targeting Diet-Microbiome Interactions in the Pathogenesis of Parkinson's Disease

W81XWH-17-0587

PD160030 P2



PI Ali Keshavarzian MD

Org: Rush University Medical Center


Award Amount: \$601,400

Study/Product Aim(s)

- Specific Aim 1. Profile the human stool microbiome, and serum and stool SCFA levels, in early PD patients.
- Specific Aim 2. Determine how the microbiome regulates gut-brain interactions in a PD model.
- Specific Aim 3. Develop and test "designer" fiber diets to modulate SCFA levels in PD mice.
- Specific Aim 4. Test dietary and probiotic treatments in mice with PD-like symptoms.

Approach

The current project will analyze the gut microbiome and metabolites from PD patients and controls, and employ clinically relevant mouse models to determine how metabolites produced by the microbiome from dietary substrates affect motor symptoms. We propose to test whether directly regulating microbial metabolite profiles using "designer" dietary fibers and probiotics offers new avenues for ameliorating PD-like symptoms.



Timeline and Cost

Activities	CY	17	18	19	20
Recruitment & Sequencing		[Progress bar]			
Animal Colonization			[Progress bar]		
Fiber Testing in Animals			[Progress bar]		
Estimated Budget (\$K)		706,545	857,941	861,612	731,637

Updated: (June 15, 2019)

Goals/Milestones (Example)

CY17 Goal – Subject Recruitment and initial animal colonization

- Subject recruitment and sample collection
- Colonization of mice with human microbiota
- Motor testing and neuroinflammatory status
- Treat PD mice with fibers, motor test

CY18 Goals – Fiber testing and animal studies

CY19 Goal – Fiber optimization and animal studies, microglia profile

CY20 Goal – Integrated multi-omics analysis of human and mouse data

Comments/Challenges/Issues/Concerns

- No issues to report

- **Rush University Budget Expenditure Y3:**
- **Year 3 budget expenditure: \$153,878.**